ClinConnect ClinConnect Logo
Search / Trial NCT06898996

FITting Non-invasive Tests in Lynch Syndrome Surveillance

Launched by UNIVERSITY OF CHICAGO · Mar 20, 2025

Trial Information

Current as of April 29, 2025

Not yet recruiting

Keywords

Lynch Syndrome Colorectal Cancer

ClinConnect Summary

This clinical trial, called "FITting Non-invasive Tests in Lynch Syndrome Surveillance," is looking to compare two different tests for monitoring patients with Lynch Syndrome, a genetic condition that increases the risk of colorectal cancer. The study will evaluate how well a simple stool test called the fecal immunochemical test (FIT) works compared to the more invasive colonoscopy, which is a procedure where a doctor looks inside the colon using a camera. The goal is to see if the stool test can be a reliable alternative for regular check-ups in these patients.

To be eligible for the trial, participants need to have a confirmed diagnosis of Lynch Syndrome and be between the ages of 20 and 75, depending on the specific genetic variant they carry. They must also have a colonoscopy scheduled as part of their regular care. Unfortunately, individuals who have had certain surgeries, are pregnant, or have other specific health issues will not be able to join the study. If you participate, you can expect to take both the stool test and undergo a colonoscopy, allowing researchers to compare the results from both methods. This trial aims to improve the way we monitor people with Lynch Syndrome and potentially make screening easier and less invasive.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Have a diagnosis of LS with a confirmed pathogenic variant in MLH1, MSH2, MSH6, PMS2 or EPCAM genes.
  • Aged 20 - 75 years
  • Have an upcoming standard of care (SOC) colonoscopy appointment in line with standard LS surveillance guidelines (NCCN).
  • Willing to sign informed consent, collect stools samples and complete surveys
  • Exclusion Criteria:
  • Individuals who have not proceeded with genetic testing and therefore are not known to have LS, despite family history and/or criteria for testing.
  • Individuals who have previously undergone a subtotal or total colectomy.
  • Newly diagnosed Lynch Syndrome patients \< 20 years old with a pathogenic variant in MLH1, MSH2 or EPCAM, MSH6 or PMS2.
  • Individuals who are pregnant.
  • Individuals with inflammatory bowel disease or active malignancy.
  • Individuals not willing or able to sign informed consent.

About University Of Chicago

The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.

Locations

Ann Arbor, Michigan, United States

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Sonia Kupfer, MD

Principal Investigator

University of Chicago

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported